TITLE

New Merck drug plays catch-up

AUTHOR(S)
Goetzl, David; Petrecca, Laura
PUB. DATE
November 1999
SOURCE
Advertising Age;11/22/1999, Vol. 70 Issue 48, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Discusses the launching of the drug Vioxx by Merck & Co. to catch up to the market leader Celebrex. How Vioxx received approval from the United States Food & Drug Administration; Why the Vioxx advertising campaign will be more wire-reaching than the Celebrex campaign; Use of both drugs in relieving arthritis pain.
ACCESSION #
2512381

 

Related Articles

  • Vytorin Labeling Updated.  // Monthly Prescribing Reference;Mar2012, Vol. 28 Issue 3, pA-20 

    The article offers information on the approval of updated labeling of the drug Vytorin from Merck and Co. Inc. by the U.S. Food and Drug Administration.

  • Pharma: Other News To Note.  // BioWorld Today;2/14/2012, Vol. 23 Issue 21, p8 

    the article reports on the approval of Zioptan (tatfluprost ophthalmic solution) from Merck & Co. Inc. by the U.S. Food and Drug Administration (FDA) for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

  • Pharma: Other News To Note.  // BioWorld Today;5/9/2013, Vol. 24 Issue 89, p6 

    The article reports on the acceptance of investigational ragweed pollen sublingual allergy immunotherapy tablet by Merck & Co. Inc. for review by the U.S. Food and Drug Administration (FDA).

  • Merck's Zioptan Joins Prostaglandin Market.  // Review of Ophthalmology;Apr2012, Vol. 19 Issue 4, p114 

    The article reports that the use of Zioptan 0.0015%, an analog ophthalmic solution from Merck & Co. Inc., for reducing elevated intraocular pressure in individuals with ocular hypertension or open-angle glaucoma has been approved by the U.S. Food and Drug Administration (FDA).

  • Help-seeking ads unhelpful: Merck. M. A. // Medical Marketing & Media;Apr2010, Vol. 45 Issue 4, p26 

    The article presents the criticisms of Merck & Co. Inc. on Food and Drug Administration's (FDA) lack of transparency in drug advertising in the U.S.

  • FDA accepts Merck's drug application. Zanki, Tom // njbiz;9/16/2013, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved pharmaceutical company Merck & Co. Inc.'s drug application for corifollitropin alfa, its investigational fertility medicine.

  • New safety recommendations for high-dose simvastatin.  // Pharmacy Today;Jul2011, Vol. 17 Issue 7, p2 

    The article reports that Merck & Co. Inc. and the U.S. Food and Drug Administration (FDA) announced that were changes on the prescribing information for drugs with high doses of simvastatin to reflect findings regarding the increased risk of myopathy, which include rhabdomyolysis.

  • Merck Wins an Approval.  // Chain Drug Review;4/25/2011, Vol. 33 Issue 8, p218 

    The article reports on the approval of Sylatron, a melanoma treatment from Merck & Co. Inc., by the U.S. Food and Drug Administration (FDA) in 2011.

  • Eye Pressure Medication Gets Approval From the FDA.  // Chain Drug Review;3/26/2012, Vol. 34 Issue 6, p66 

    The article reports on the approval of several medications by the U.S. Food and Drug Administration including eye pressure remover Zioptan from Merck & Co. Inc., head lice remedy Sklice from Sanofi Pasteur SA and Avonex Pen injector for multiple sclerosis from Biogen Idec Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics